AlphaMol Science

Executive Summary

AlphaMol Science is a Swiss biotechnology company headquartered in Basel, founded in 2016, that specializes in developing small molecule therapeutics to disrupt challenging protein-protein interactions (PPIs) for oncology and other diseases. Operating in a high-potential yet technically difficult area of drug discovery, the company leverages its expertise to target PPIs, which are notoriously difficult to modulate with small molecules but offer significant therapeutic opportunities. Despite being in the early stages of development without disclosed funding or pipeline specifics, AlphaMol's focus on a cutting-edge approach positions it to address unmet medical needs in oncology. The company's private status and limited public information suggest it is still in the preclinical or early clinical phase, requiring validation through future milestones. AlphaMol's strategy centers on tackling a class of targets that have historically been considered "undruggable," which could yield first-in-class therapies if successful. The biotech landscape for PPI inhibitors is competitive but growing, with several companies pursuing similar approaches. AlphaMol's Swiss base provides access to a strong pharmaceutical ecosystem. However, the technical risks are high, and the lack of disclosed data makes it difficult to assess probability of success. Near-term catalysts could provide clarity on the company's progress and differentiation.

Upcoming Catalysts (preview)

• Q2 2027IND filing for lead PPI inhibitor program40% success
• Q4 2026Series A financing round completion60% success
• Q2 2026Presentation of preclinical data at major oncology conference70% success